Compare TG & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TG | OBIO |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.5M | 246.2M |
| IPO Year | 1994 | 2020 |
| Metric | TG | OBIO |
|---|---|---|
| Price | $8.32 | $4.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | 120.7K | ★ 183.6K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 151.06 | 33.13 |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $800,821,000.00 | $33,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.43 |
| P/E Ratio | $8.53 | ★ N/A |
| Revenue Growth | 8.29 | ★ 1169.22 |
| 52 Week Low | $6.25 | $2.20 |
| 52 Week High | $9.66 | $5.42 |
| Indicator | TG | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.62 | 50.14 |
| Support Level | $7.52 | $4.02 |
| Resistance Level | $9.26 | $4.88 |
| Average True Range (ATR) | 0.29 | 0.26 |
| MACD | 0.10 | -0.04 |
| Stochastic Oscillator | 91.85 | 41.77 |
Tredegar Corp, through its subsidiaries, engages in the manufacture of polyethylene plastic films, polyester films, and aluminum extrusions. Polyethylene plastic films produce plastic films, elastics, and laminate materials that are used in personal care products, surface protection films, and specialty and optical lighting applications. The company operates through segments including PE films, flexible packaging films, and aluminum extrusions. Aluminum extrusions generate the majority of revenue and provide high-quality, soft-alloy, medium-strength aluminum utilized in the building and construction, automotive, consumer durables, machinery and equipment, electrical, and distribution markets. Revenue is generated from the United States, Asia, and Brazil.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.